PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsCommentShould prenatal DNA testing for Down's syndrome be available online?

BioNews

Should prenatal DNA testing for Down's syndrome be available online?

Published 25 October 2016 posted in Comment and appears in BioNews 874

Author

Craig Macpherson

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on Auguste Rodin's 'The Thinker').
CC BY 4.0
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on the sculpture 'The Thinker' by Auguste Rodin).

Several online companies now offer non-invasive prenatal testing for Down's syndrome. While there are some protections for consumers, they are currently insufficient...

Tests to detect whether an unborn baby will be born with Down's syndrome have long been part of prenatal care in the UK. Current tests measure hormones and proteins in the mother's blood, and for those whose fetus shows a high risk of the condition, invasive tests are offered. This involves inserting a long needle into the amniotic sac or placenta, and carries a one to two percent risk of miscarriage.

The development of non-invasive, genetic-based alternatives has therefore attracted attention – not just from the medical community, but also from the general public. The recent BBC documentary A World Without Down's Syndrome? reveals that these developments aren't universally regarded as positive. Aside from the ethical issues that were touched on in the programme, there are other, practical concerns associated with these tests.

Non-invasive prenatal DNA testing (NIPT) for Down's syndrome doesn't increase the risk of miscarriage, and studies have shown it to be 99 percent accurate. The UK National Screening Committee has recommended that NIPT be adopted by the NHS, but it’s been privately available for several years to those who are willing (and able) to pay for it. In most cases, pregnant women must consult a doctor at a specialist private clinic who will order the test, take a blood sample, and deliver the results in person. Another option offered by a few UK companies is to buy the test online, independently of a medical professional. In this case, the sample collection kit isn't sent directly to the customer (unlike most direct-to-consumer DNA tests) but to their doctor, who will be required to take the blood sample. So, should NIPT be offered directly to the public? If so, what protections should be provided?

One of the major issues associated with NIPT is genetic counselling. While the few companies that offer NIPT online recommend that the customer ask their doctor about the test, the companies don't offer genetic counselling as part of the service. As this technology is still relatively new, and not yet available on the NHS, it's understandable that doctors may not be able to provide all the answers and shouldn’t be exclusively relied on to do so. 

Genetic counselling before NIPT is purchased would ensure that expectant parents fully understand the potential implications and significance of the results, as well as exactly what the test involves and how accurate it is. The provision of counselling after receiving the results is even more important – studies estimate that over 90 percent of those who receive a prenatal diagnosis for Down's syndrome choose to terminate their pregnancy, illustrating the importance of an accurate interpretation of the results.

The relevant EU legislation that covers direct-to-consumer DNA tests is the IVD Directive (In Vitro Diagnostic Medical Devices Directive). As it currently stands, there is no requirement for genetic counselling to be provided with any type of direct-to-consumer DNA test. However, forthcoming updates will require genetic counselling to be offered with DNA tests for untreatable conditions, which will include Down's syndrome, and therefore NIPT. Updates to the IVD Directive are due to go through in 2017 but may be delayed until 2018, and after Brexit there's no guarantee that the UK will regulate DNA tests accordingly.

Until companies selling online NIPT are required by law to provide genetic counselling to customers purchasing the tests, the significance of a positive result for Down’s syndrome raises an important question: should companies be prevented from offering NIPT for untreatable conditions before the updated IVD Directive takes effect?

The companies that currently sell NIPT online appear to have some reassuring protections in place. An informed consent form must be signed by the participant, which contains information about the purpose, procedure and potential results of the test. They also specify that, as well as sending the sample collection kit sent directly to the customer’s doctor, they will also return the results to the doctor. This means that customers must book a consultation with their doctor in order to receive their results, ensuring that they don’t interpret the results alone.

These provisions are promising and rival those of private clinics, which often charge higher prices and are only available in certain locations. But it's not difficult to imagine a customer who completes a consent form without truly understanding it, therefore without demonstrating informed consent. Coupled with the fact that the customer's doctor is unlikely to have the skills to conduct genetic counselling, this leaves the customer exposed to potentially life-changing information without the appropriate support.

It should be noted that an important advantage of online NIPT is the increased availability and affordability it offers, allowing wider access to the service. The way in which this market develops will likely depend on whether the NHS begins to offer NIPT as part of standard prenatal care. With pressure from Down's syndrome advocacy campaigns such as Don't Screen Us Out, this isn’t a forgone conclusion, but if NIPT isn't conducted by the NHS as standard, the popularity of online tests is likely to increase.

Competition will bring prices down and provide wider access to NIPT for Down’s syndrome, but until the IVD Directive is updated and enforced, I believe that selling this service online comes with too great a risk. The news that your baby has Down’s syndrome can be surprising, overwhelming and even devastating, and imparting this news is a great responsibility that must not be taken lightly.

Related Articles

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
News
13 November 2017 • 3 minutes read

Prenatal test for Down's syndrome recommended for NHS

by Dr Lone Hørlyck

A new blood test for Down’s syndrome in high-risk women has been recommended for use on the NHS....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
25 April 2017 • 3 minutes read

Use of prenatal tests 'must be limited', say bioethicists

by Emma Laycock

The Nuffield Council on Bioethics has called for a ban on using early prenatal testing to find out the sex or sequence the whole genome of the fetus...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on Auguste Rodin's 'The Thinker').
CC BY 4.0
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on the sculpture 'The Thinker' by Auguste Rodin).
Comment
18 October 2016 • 5 minutes read

Down's syndrome: NIPT in the bud?

by Victoria Woodham

The introduction of non-invasive prenatal testing in the NHS screening programme for pregnant women may seem like a no-brainer, but it is based on outdated ideas of what life is like for people with Down's syndrome and their families...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on Auguste Rodin's 'The Thinker').
CC BY 4.0
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on the sculpture 'The Thinker' by Auguste Rodin).
Reviews
10 October 2016 • 4 minutes read

TV Review: A world without Down's syndrome?

by Evelyn Jager

In this documentary, Sally Phillips argues that individuals are more than just their biological characteristics and their potential health problems. But, if we view people in these terms, it's all too easy to ignore what fantastic qualities they might end up having too...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on Auguste Rodin's 'The Thinker').
CC BY 4.0
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on the sculpture 'The Thinker' by Auguste Rodin).
Comment
1 September 2016 • 3 minutes read

Why information and choice won't solve all of NIPT's ethical problems

by Professor Ainsley Newson

Jane Fisher and Lyn Chitty highlight in BioNews 864 that it's been almost nine months since the UK National Screening Committee recommended an 'evaluative implementation of NIPT into the NHS's antenatal screening programme — a recommendation that still awaits ministerial decision...

PET BioNews
Comment
16 August 2016 • 5 minutes read

NIPT or not to NIPT — is that really the question?

by Jane Fisher and 1 others

A central tenet of prenatal testing is to promote reproductive autonomy by providing women with information that can assist in pregnancy management. Bringing NIPT into the NHS will improve an established screening programme...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Down's syndrome: NIPT in the bud?

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
25 July 2022 • 4 minutes read

Was the Women's Health Strategy worth the wait?

25 July 2022 • 5 minutes read

200 Years of Mendel: From Peas to Personalised Medicine

18 July 2022 • 5 minutes read

The birth of genetics: celebrating 200 years of Mendel

15 July 2022 • 2 minutes read

FILM: Prioritising Patient Safety – How to Minimise Risk in Fertility Treatment

11 July 2022 • 6 minutes read

Dutch Embryos Act under revision

8 August 2022 • 4 minutes read

Citizenship and same-sex parents – about time, Sweden!

8 August 2022 • 2 minutes read

FILM: 200 Years of Mendel – From Peas to Personalised Medicine

1 August 2022 • 4 minutes read

Women's Health Strategy plans reflect rising needs of same-sex female couples

25 July 2022 • 4 minutes read

Was the Women's Health Strategy worth the wait?

25 July 2022 • 4 minutes read

Why the UK should extend the 14-day rule to 28 days

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856